Today, PNC Financial Services Group Inc. decides to keep it stake in Novo Nordisk A/S (NVO) to the level of $34,865,000

Today, PNC Financial Services Group Inc. decides to keep it stake in Novo Nordisk A/S (NVO) to the level of $34,865,000
PNC Financial Services Group Inc. lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 3.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 838,343 shares of the company’s stock after selling 29,726 shares during the period. PNC Financial Services Group Inc.’s holdings in Novo Nordisk A/S were worth $34,865,000 as of its most recent filing with the SEC.

Several other hedge funds also recently added to or reduced their stakes in NVO. Davis R M Inc. increased its stake in shares of Novo Nordisk A/S by 45.5% in the second quarter. Davis R M Inc. now owns 52,365 shares of the company’s stock valued at $2,816,000 after buying an additional 16,378 shares in the last quarter. Capstone Asset Management Co. increased its stake in shares of Novo Nordisk A/S by 2.4% in the second quarter. Capstone Asset Management Co. now owns 70,005 shares of the company’s stock valued at $3,765,000 after buying an additional 1,647 shares in the last quarter. Keel Point LLC increased its stake in shares of Novo Nordisk A/S by 9.1% in the second quarter. Keel Point LLC now owns 5,396 shares of the company’s stock valued at $290,000 after buying an additional 450 shares in the last quarter. Augustine Asset Management Inc. acquired a new stake in shares of Novo Nordisk A/S during the second quarter valued at $2,592,000. Finally, Atria Investments LLC acquired a new stake in shares of Novo Nordisk A/S during the second quarter valued at $460,000. 7.14% of the stock is currently owned by institutional investors.

Shares of Novo Nordisk A/S (NYSE:NVO) traded up 1.62% during trading on Friday, hitting $32.08. The stock had a trading volume of 1,964,090 shares. The company has a market capitalization of $81.05 billion, a PE ratio of 15.14 and a beta of 0.84. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $59.00. The firm has a 50-day moving average price of $36.94 and a 200 day moving average price of $47.47.

NVO has been the subject of several recent analyst reports. HSBC upgraded Novo Nordisk A/S from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 31st. Deutsche Bank AG upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Monday, September 12th. Jefferies Group restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Wednesday, September 14th. Morgan Stanley downgraded Novo Nordisk A/S from an “overweight” rating to an “equal weight” rating in a research report on Thursday, September 1st. Finally, Bank of America Corp. downgraded Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Monday, August 8th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Novo Nordisk A/S has an average rating of “Hold” and an average target price of $61.33.

About Novo Nordisk A/S

Related posts

Leave a Comment